Axiom Investors LLC DE Has $12.64 Million Stock Holdings in Option Care Health, Inc. $OPCH

Key Points

• Axiom Investors LLC DE increased its stake in Option Care Health by 111.2%, acquiring an additional 190,417 shares during the first quarter.
• Option Care Health reported a 15.4% increase in revenue year-over-year, posting earnings of $0.41 per share for the last quarter, surpassing analysts' expectations.
• Analysts maintain a consensus rating of "Moderate Buy" for Option Care Health, with an average target price of $35.75 following several price objective upgrades.

Axiom Investors LLC DE boosted its position in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 111.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 361,615 shares of the company's stock after purchasing an additional 190,417 shares during the period. Axiom Investors LLC DE owned approximately 0.22% of Option Care Health worth $12,638,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in OPCH. Northwestern Mutual Wealth Management Co. lifted its position in Option Care Health by 1,492.9% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 892 shares of the company's stock worth $31,000 after purchasing an additional 836 shares during the period. Brooklyn Investment Group increased its holdings in shares of Option Care Health by 186.6% in the first quarter. Brooklyn Investment Group now owns 1,198 shares of the company's stock valued at $42,000 after buying an additional 780 shares in the last quarter. Public Employees Retirement System of Ohio increased its holdings in shares of Option Care Health by 21.6% in the fourth quarter. Public Employees Retirement System of Ohio now owns 1,870 shares of the company's stock valued at $43,000 after buying an additional 332 shares in the last quarter. Bessemer Group Inc. increased its holdings in shares of Option Care Health by 62.3% in the first quarter. Bessemer Group Inc. now owns 1,560 shares of the company's stock valued at $54,000 after buying an additional 599 shares in the last quarter. Finally, Wealthquest Corp bought a new position in shares of Option Care Health in the first quarter valued at $66,000. 98.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Option Care Health

In related news, Director Timothy P. Sullivan purchased 20,000 shares of the company's stock in a transaction dated Thursday, August 21st. The shares were acquired at an average cost of $27.51 per share, with a total value of $550,200.00. Following the completion of the purchase, the director owned 49,229 shares of the company's stock, valued at $1,354,289.79. The trade was a 68.43% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Harry M. Jansen Kraemer, Jr. purchased 36,000 shares of the company's stock in a transaction dated Wednesday, August 20th. The stock was bought at an average cost of $27.15 per share, for a total transaction of $977,400.00. Following the completion of the purchase, the director directly owned 375,390 shares of the company's stock, valued at $10,191,838.50. The trade was a 10.61% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 59,411 shares of company stock valued at $1,627,576 in the last three months. 0.64% of the stock is currently owned by company insiders.

Option Care Health Stock Down 3.0%

NASDAQ:OPCH traded down $0.89 during trading hours on Friday, hitting $28.48. 1,626,043 shares of the stock traded hands, compared to its average volume of 1,842,623. The firm has a 50 day moving average price of $29.09 and a 200 day moving average price of $31.44. The company has a current ratio of 1.52, a quick ratio of 1.00 and a debt-to-equity ratio of 0.81. Option Care Health, Inc. has a fifty-two week low of $21.39 and a fifty-two week high of $35.53. The firm has a market cap of $4.62 billion, a price-to-earnings ratio of 22.78, a PEG ratio of 1.79 and a beta of 0.82.

Option Care Health (NASDAQ:OPCH - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.40 by $0.01. Option Care Health had a net margin of 3.93% and a return on equity of 17.53%. The company had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.35 billion. During the same period in the previous year, the business earned $0.30 EPS. The company's revenue was up 15.4% on a year-over-year basis. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. Equities research analysts anticipate that Option Care Health, Inc. will post 1.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on OPCH shares. JMP Securities upped their price target on Option Care Health from $36.00 to $38.00 and gave the company a "market outperform" rating in a report on Thursday, July 31st. Barrington Research reaffirmed an "outperform" rating and issued a $38.00 price target on shares of Option Care Health in a report on Thursday, July 10th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Option Care Health in a report on Thursday, July 31st. Eight research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $35.75.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.